An EZH2 inhibitor has been tested in patients with relapsed or refractory B-cell lymphoma and advanced solid tumors, showing a favorable safety profile [91], though it has not yet been tested in MDS/AML as the majority of cases harbor loss-of-function PRC2 mutations. This evidence concerns the gene EZH2 and myelodysplastic syndrome.